Zobrazeno 1 - 10
of 605
pro vyhledávání: '"S. Davids"'
Autor:
Alberto J. Arribas, Sara Napoli, Eugenio Gaudio, Charles Herbaux, Eleonora Cannas, Chiara Tarantelli, Roberta Bordone-Pittau, Luciano Cascione, Nicolas Munz, Luca Aresu, Jacopo Sgrignani, Andrea Rinaldi, Ivo Kwee, Davide Rossi, Andrea Cavalli, Emanuele Zucca, Georg Stussi, Anastasios Stathis, Callum Sloss, Matthew S. Davids, Francesco Bertoni
Publikováno v:
Blood Advances, Vol 8, Iss 24, Pp 6268-6281 (2024)
Abstract: CD37-directed antibody and cellular-based approaches have shown preclinical and promising early clinical activity. Naratuximab emtansine (Debio 1562; IMGN529) is an antibody-drug conjugate (ADC) incorporating an anti-CD37 monoclonal antibod
Externí odkaz:
https://doaj.org/article/f13d1f95148f4ba0b57e2b41397d19d2
Autor:
Roberta S. Azevedo, Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva, Stacey Fernandes, Samantha Shupe, Marissa Terra, Anisha Patel, Matthew S. Davids, Joseph Yu, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Chronic lymphocytic leukemia (CLL) patients have an increased risk of secondary cancers, along with predisposition to CLL in their relatives. We have previously identified germline ATM variants as associated with CLL risk; here, we present their impa
Externí odkaz:
https://doaj.org/article/97a85dd3b87e4eada3214a8ce2c22660
Autor:
S. Stilgenbauer, E. Tausch, A. W. Roberts, M. S. Davids, B. Eichhorst, M. Hallek, P. Hillmen, C. Schneider, S. Böttcher, R. Popovic, M. T. Ghanim, M. Moran, W. J. Sinai, X. Wang, N. Mukherjee, B. Chyla, W. G. Wierda, J. F. Seymour
Publikováno v:
HemaSphere, Vol 6, Pp 47-48 (2022)
Externí odkaz:
https://doaj.org/article/7176cf0f3fb2482e8cc0556a6086b189
Autor:
A. R. Mato, J. M. Pagel, C. C. Coombs, N. N. Shah, N. Lamanna, T. Munir, E. Lech-Maranda, T. A. Eyre, J. A. Woyach, W. G. Wierda, C. Y. Cheah, J. B. Cohen, L. E. Roeker, M. R. Patel, B. Fakhri, M. A. Barve, C. Tam, D. Lewis, J. N. Gerson, A. J. Alencar, C. Ujjani, I. Flinn, S. Sundaram, S. Ma, D. Jagadeesh, J. Rhodes, J. Taylor, O. Abdel-Wahab, P. Ghia, S. J. Schuster, D. Wang, B. Nair, E. Zhu, D. E. Tsai, M. S. Davids, J. R. Brown, W. Jurczak
Publikováno v:
HemaSphere, Vol 6, Pp 48-49 (2022)
Externí odkaz:
https://doaj.org/article/9c904aa8c5544561ab89c6966cbec755
Autor:
A. R. Mato, B. S. Manzoor, C. C. Coombs, N. Lamanna, H. H. Tuncer, J. R. Brown, L. E. Roeker, M. Shadman, J. N. Allan, C. Ujjani, B. Eichhorst, L. Leslie, I. Fleury, H. Alhasani, J. Rhodes, B. T. Hill, P. M. Barr, A. Skarbnik, M. S. Davids, R. Bannerji, M. Fuldeore, F. Lansigan, A. Schuh, L. Pearson, C. P. Fox, I. Pivneva, L. Popadic, A. Guerin, T. A. Eyre
Publikováno v:
HemaSphere, Vol 6, Pp 569-570 (2022)
Externí odkaz:
https://doaj.org/article/8f7acc4b3eac4168becfee180d24abb1
Autor:
M. S. Davids, J. Richter, C. Anderson-Smits, M. Kamieniak, K. Ren, M. Hull, J. Multani, D. Shah, C. Siffel
Publikováno v:
HemaSphere, Vol 6, Pp 1463-1464 (2022)
Externí odkaz:
https://doaj.org/article/571fc52edfb64179b8c4e52e0671f2b3
Autor:
A. R. Mato, W. G. Wierda, J. M. Pagel, M. S. Davids, P. L. Zinzani, Y. Lu, H. Liu, S. Shahda, C. C. Leow, C. S. Tam, J. A. Woyach, T. A. Eyre
Publikováno v:
HemaSphere, Vol 6, Pp 1743-1744 (2022)
Externí odkaz:
https://doaj.org/article/c78552d021a442568ce7eee2bb1d7548
Autor:
Steven P. Treon, Ann S. LaCasce, Sally Tan, Anna K. Dewan, Matthew S. Davids, Nicole R. LeBoeuf, Sean Singer
Publikováno v:
Journal of the American Academy of Dermatology. 88:1271-1281
Background Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK) that is FDA-approved for several lymphoproliferative disorders and chronic GVHD. Objective To characterize cutaneous eruptions arising from ibrutinib and highlight overlap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bda5464e52e9cca64e1f65e3d46f27ed
https://doi.org/10.1016/j.jaad.2019.12.031
https://doi.org/10.1016/j.jaad.2019.12.031
Autor:
Sikander Ailawadhi, Zi Chen, Bo Huang, Aneel Paulus, Mary C. Collins, Lei (Tommy) Fu, Mingyu Li, Mohammad Ahmad, Lichuang Men, Hengbang Wang, Matthew S. Davids, Eric Liang, Divya J. Mekala, Zhicong He, Masa Lasica, Costas K. Yannakou, Ricardo Parrondo, Laura Glass, Dajun Yang, Asher Chanan-Khan, Yifan Zhai
Publikováno v:
Clinical Cancer Research. :OF1-OF9
Purpose: This global phase I trial investigated the safety, efficacy, pharmacokinetics, and pharmacodynamics of lisaftoclax (APG-2575), a novel, orally active, potent selective B-cell lymphoma 2 (BCL-2) inhibitor, in patients with relapsed or refract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd60a77b52bdc782d087af16a7899d7d
https://doi.org/10.1158/1078-0432.ccr-22-3321
https://doi.org/10.1158/1078-0432.ccr-22-3321
Autor:
Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S. Kim, Stacey M. Fernandes, Gordon Saksena, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, James A. Lederer, Rula Zain, C. I. Edvard Smith, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown
Publikováno v:
Blood Advances. 7:1929-1943
Covalent inhibitors of Bruton tyrosine kinase (BTK) have transformed the therapy of chronic lymphocytic leukemia (CLL), but continuous therapy has been complicated by the development of resistance. The most common resistance mechanism in patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8383f4c725051ef015310abdc3f2d39
https://doi.org/10.1182/bloodadvances.2022008447
https://doi.org/10.1182/bloodadvances.2022008447